SEARCH

SEARCH BY CITATION

References

  • 1
    Schultz Larsen F. Atopic dermatitis: a genetic-epidemiologic study in a population-based twin sample. J Am Acad Dermatol 1993;28: 719723.
  • 2
    Mosmann TR, Sad S. The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol Today 1996;17: 138146.
  • 3
    Grewe M, Bruijnzeel-Koomen CA, Schopf E, Thepen T, Langeveld-Wildschut AG, Ruzicka T et al. A role for Th1 and Th2 cells in the immunopathogenesis of atopic dermatitis. Immunol Today 1998;19: 359361.
  • 4
    Hansen G, Berry G, DeKruyff RH, Umetsu DT. Allergen-specific Th1 cells fail to counterbalance Th2 cell-induced airway hyperreactivity but cause severe airway inflammation. J Clin Invest 1999;103: 175183.
  • 5
    Letterio JJ, Roberts AB. Regulation of immune responses by TGF-beta. Annu Rev Immunol 1998;16: 137161.
  • 6
    Hobbs K, Negri J, Klinnert M, Rosenwasser LJ, Borish L. Interleukin-10 and transforming growth factor-beta promoter polymorphisms in allergies and asthma. Am J Respir Crit Care Med 1998;158: 19581962.
  • 7
    Anderson GG, Morrison JF. Molecular biology and genetics of allergy and asthma. Arch Dis Child 1998;78: 488496.
  • 8
    Forrest S, Dunn K, Elliott K, Fitzpatrick E, Fullerton J, McCarthy M et al. Identifying genes predisposing to atopic eczema. J Allergy Clin Immunol 1999;104: 10661070.
  • 9
    Ono SJ. Molecular genetics of allergic diseases. Annu Rev Immunol 2000;18: 347366.
  • 10
    Meda L, Baron P, Prat E, Scarpini E, Scarlato G, Cassatella MA et al. Proinflammatory profile of cytokine production by human monocytes and murine microglia stimulated with beta-amyloid[25–35]. J Neuroimmunol 1999;93: 4552.
  • 11
    Eigler A, Matschke V, Hartmann G, Erhardt S, Boyle D, Firestein GS et al. Suppression of TNF-alpha production in human mononuclear cells by an adenosine kinase inhibitor. J Leukoc Biol 2000;68: 97103.
  • 12
    Hanifin JMRG. Diagnostic features of atopic dermatitis. Acta Derm Venereol 1980;92(Suppl.):4447.
  • 13
    Eichenfield LF. Consensus guidelines in diagnosis and treatment of atopic dermatitis. Allergy 2004;59(Suppl. 78):8692.
  • 14
    Gelmetti C, Colonna C. The value of SCORAD and beyond. Towards a standardized evaluation of severity? Allergy 2004;59(Suppl. 78):6165.
  • 15
    Kang SBLS, Kim JW, Kim JK, Kim CW. Total serum IgE level in each age group of patients with atopic dermatitis. Korean J Dermatol 1988;26: 507512.
  • 16
    Makridakis NM, Reichardt JK. Multiplex automated primer extension analysis: simultaneous genotyping of several polymorphisms. Biotechniques 2001;31: 13741380.
  • 17
    Shin HD, Winkler C, Stephens JC, Bream J, Young H, Goedert JJ et al. Genetic restriction of HIV-1 pathogenesis to AIDS by promoter alleles of IL10. Proc Natl Acad Sci U S A 2000;97: 1446714472.
  • 18
    Shin HD, Kim LH, Park BL, Jung JH, Kim JY, Chung IY et al. Association of eotaxin gene family with asthma and serum total IgE. Hum Mol Genet 2003;12: 12791285.
  • 19
    Redpath S, Ghazal P, Gascoigne NR. Hijacking and exploitation of IL-10 by intracellular pathogens. Trends Microbiol 2001;9: 8692.
  • 20
    Rosenwasser LJ, Borish L. Genetics of atopy and asthma: the rationale behind promoter-based candidate gene studies (IL-4 and IL-10). Am J Respir Crit Care Med 1997;156: S152155.
  • 21
    Rees LE, Wood NA, Gillespie KM, Lai KN, Gaston K, Mathieson PW. The interleukin-10-1082 G/A polymorphism: allele frequency in different populations and functional significance. Cell Mol Life Sci 2002;59: 560569.
  • 22
    Turner DM, Williams DM, Sankaran D, Lazarus M, Sinnott PJ, Hutchinson IV. An investigation of polymorphism in the interleukin-10 gene promoter. Eur J Immunogenet 1997;24: 18.
  • 23
    Zhang J, Chen H, Hu L, Fu J, Zhang H, Chen Y. Correlation between polymorphism of IL-4 and IL-10 gene promoter and childhood asthma and their impact upon cytokine expression. Zhonghua Yi Xue Za Zhi 2002;82: 114118.
  • 24
    Edwards-Smith CJ, Jonsson JR, Purdie DM, Bansal A, Shorthouse C, Powell EE. Interleukin-10 promoter polymorphism predicts initial response of chronic hepatitis C to interferon alfa. Hepatology 1999;30: 526530.
  • 25
    Crawley E, Kay R, Sillibourne J, Patel P, Hutchinson I, Woo P. Polymorphic haplotypes of the interleukin-10 5′ flanking region determine variable interleukin-10 transcription and are associated with particular phenotypes of juvenile rheumatoid arthritis. Arthritis Rheum 1999;42: 11011108.
  • 26
    Vidigal PG, Germer JJ, Zein NN. Polymorphisms in the interleukin-10, tumor necrosis factor-alpha, and transforming growth factor-beta1 genes in chronic hepatitis C patients treated with interferon and ribavirin. J Hepatol 2002;36: 271277.
  • 27
    Yee LJ, Tang J, Gibson AW, Kimberly R, Van Leeuwen DJ, Kaslow RA. Interleukin 10 polymorphisms as predictors of sustained response in antiviral therapy for chronic hepatitis C infection. Hepatology 2001;33: 708712.
  • 28
    Grove J, Daly AK, Bassendine MF, Gilvarry E, Day CP. Interleukin 10 promoter region polymorphisms and susceptibility to advanced alcoholic liver disease. Gut 2000;46: 540545.
  • 29
    Helminen ME, Kilpinen S, Virta M, Hurme M. Susceptibility to primary Epstein-Barr virus infection is associated with interleukin-10 gene promoter polymorphism. J Infect Dis 2001;184: 777780.
  • 30
    Wu MS, Huang SP, Chang YT, Shun CT, Chang MC, Lin MT et al. Tumor necrosis factor-alpha and interleukin-10 promoter polymorphisms in Epstein-Barr virus-associated gastric carcinoma. J Infect Dis 2002;185: 106109.
  • 31
    Stanczuk GA, Sibanda EN, Perrey C, Chirara M, Pravica V, Hutchinson IV et al. Cancer of the uterine cervix may be significantly associated with a gene polymorphism coding for increased IL-10 production. Int J Cancer 2001;94: 792794.
  • 32
    Zheng C, Huang D, Liu L, Wu R, Bergenbrant Glas S, Osterborg A et al. Interleukin-10 gene promoter polymorphisms in multiple myeloma. Int J Cancer 2001;95: 184188.
  • 33
    Shin HD, Park BL, Kim LH, Jung JH, Kim JY, Yoon JH et al. Interleukin 10 haplotype associated with increased risk of hepatocellular carcinoma. Hum Mol Genet 2003;12: 901906.
  • 34
    Howell WM, Turner SJ, Bateman AC, Theaker JM. IL-10 promoter polymorphisms influence tumour development in cutaneous malignant melanoma. Genes Immun 2001;2: 2531.
  • 35
    Asadullah K, Eskdale J, Wiese A, Gallagher G, Friedrich M, Sterry W. Interleukin-10 promoter polymorphism in psoriasis. J Invest Dermatol 2001;116: 975978.
  • 36
    Reich K, Garbe C, Blaschke V, Maurer C, Middel P, Westphal G et al. Response of psoriasis to interleukin-10 is associated with suppression of cutaneous type 1 inflammation, downregulation of the epidermal interleukin-8/CXCR2 pathway and normalization of keratinocyte maturation. J Invest Dermatol 2001;116: 319329.
  • 37
    Jeannin P, Lecoanet S, Delneste Y, Gauchat JF, Bonnefoy JY. IgE versus IgG4 production can be differentially regulated by IL-10. J Immunol 1998;160: 35553561.